Quantum BioPharma Ltd Stock Price, News & Analysis

Quantum BioPharma (NASDAQ:QNTM) presents a hybrid issuer model combining neuroscience drug development, consumer-health commercialization, and market-access technology to create a "digital balance-sheet framework."

Key elements: flagship neuroprotective program Lucid-MS (Lucid-21-302), a PET imaging collaboration with Massachusetts General Hospital to track remyelination, a consumer brand Celly Nu with the unbuzzd beverage (royalty: 7% until $250M paid, then 3% in perpetuity), and a dual listing on Upstream approved in January 2025 to enable near-instant settlement and broader investor access.

Quantum BioPharma (NASDAQ: QNTM) set October 27, 2025 as the record date to distribute contingent value rights (CVRs) to holders of its Class B subordinate voting shares on a one-for-one basis. Each CVR entitles holders to a pro rata share of a minimum of 10% and up to 50% of the net proceeds the company ultimately recovers from its litigation alleging stock price manipulation and spoofing, which seeks damages in excess of USD $700 million. No payments will be made unless and until the company receives Qualifying Net Proceeds following a settlement or a final, non-appealable judgment. The CVRs will be non-transferable, unlisted, non-voting, non-interest bearing, redeemable only for cash upon receipt of Qualifying Net Proceeds, and the distribution date remains undetermined.

Quantum BioPharma (NASDAQ: QNTM) has reached a significant milestone in the development of Lucid-21-302 (Lucid-MS), its potential breakthrough drug for Multiple Sclerosis. The company received final reports for two critical studies: the 90-day oral toxicity study and the toxicokinetic study.

These reports will support Quantum's Investigational New Drug (IND) application to the US FDA for a planned Phase 2 clinical trial. Lucid-MS is being developed as a first-in-class treatment targeting demyelination in Multiple Sclerosis patients.

Quantum BioPharma (NASDAQ: QNTM) has announced the appointment of Dr. Jack Antel, a world-renowned multiple sclerosis expert, as clinical advisor for its MS program focused on Lucid-21-302 (Lucid-MS). Dr. Antel will advise on the clinical development and efficacy trial design for Lucid-MS, a patented investigational drug designed to inhibit demyelination in MS.

Dr. Antel brings significant expertise as a Professor of Neurology at McGill University and former National Scientific Director of the endMS Research and Training Network. He has published over 450 scientific articles and held prestigious positions including Chairman of the Medical Advisory Board of the Multiple Sclerosis Society of Canada and President of ACTRIMS.

He will join existing advisor Dr. Peter Stys, Professor of Neurosciences at the University of Calgary, to support Quantum's development of Lucid-MS toward Phase 2 clinical trials.

Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders treatments, held its annual general and special meeting of shareholders on September 26, 2025. The meeting saw strong participation with 100% of Class A Multiple Voting Shares and 46.352% of Class B Subordinate Voting Shares represented.

All seven nominated directors were successfully elected with over 99.6% approval rates. Shareholders also approved the re-appointment of MNP LLP as auditor with 99.588% support and authorized the potential issuance of up to 56 additional Class A Multiple Voting Shares, receiving 90.992% approval from eligible Class B shareholders.

Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders treatments, has announced key corporate updates regarding equity compensation. The Board approved the grant of 32,000 restricted share units (RSUs) to three key executives, which will vest upon completion of Phase 2 MS Study data compilation.

Additionally, the company granted 98,000 stock options to directors, officers, employees, and consultants at C$24.50 per Class B Share, with immediate vesting and expiration on September 24, 2030. Both grants are subject to a four-month statutory hold period and constitute related party transactions under MI 61-101, though qualifying for exemptions from formal valuation and minority shareholder approval requirements.

Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness, will host an investor webinar on October 1, 2025 at 4:30 PM EST to discuss its Regulation D 506(c) offering aiming to raise up to $5 million.

The webinar will feature presentations from key executives including CEO John Duffy, discussing Unbuzzd's clinically proven beverage that accelerates alcohol metabolism and reduces hangover symptoms. The company plans to use the funds for direct-to-consumer expansion, distributor and retail growth, and to establish a path toward a potential IPO. Importantly, Quantum BioPharma shareholders will not face dilution from this offering.